Substituted 10-aryl-11

1. A compound, or a pharmaceutically acceptable salt thereof, having the formula 1,

wherein:

R e and ′R e are OH, optionally independently etherified or esterified;

Z is —C(R 4 ,R 5 )—, wherein R 4 and R 5 are independently (1C-2C)alkyl or form together a spiro(3C-5C)cycloalkyl;

R 1 is H, halogen, CF 3 , or (1C-4C)alkyl;

R 2 and R 3 are independently H, halogen, —CF 3 , —OCF 3 , (1C-8C)alkyloxy, aryloxy, aryl(1C-8C)alkyl, halo(1C-8C)alkyl, —O(CH 2 ) m ,X, wherein X is halogen or phenyl and m=2-4; —O(CH 2 ) m NR a R b , —S(CH 2 ) m NR a R b or —(CH 2 ) m NR a R b , wherein m=2-4 and wherein R a , R b are independently (1C-8C)alkyl, (2C-8C)alkenyl, (2C-8C)alkynyl, or aryl, which alkyl, alkenyl and aryl can optionally be substituted with halogen, —CF 3 , —OCF 3 , —CN, —NO 2 , —OH, (1C-8C)alkoxy, aryloxy, carboxyl, (1C-8C)alkylthio, carboxylate, (1 C-8C)alkyl, aryl, aryl(1C-8C)alkyl or halo(1C-8C)alkyl; or R a and R b form a 3-8 membered ring structure, optionally substituted with halogen, —CF 3 , —OCF 3 , —CN, —NO 2 , hydroxy, hydroxy(1C-4C)alkyl, (1C-8C)alkoxy, aryloxy, (1C-8C)alkylthio, carboxyl, carboxylate, (1C-8C)alkyl, aryl, aryl(1C-8C)alkyl, halo(1 C-8C)alkyl.

2. The compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , wherein R 3 is H and R 2 is —O(CH 2 ) m NR a R b , —S(CH 2 ) m NR a R b or —(CH 2 ) m NR a R b , wherein m=2-4 and wherein R a , R b are independently (1C-8C)alkyl, (2C-8C)alkenyl, (2C-8C)alkynyl, or aryl, which alkyl, alkenyl and aryl can be optionally substituted with halogen, —CF 3 , —OCF 3 , —CN, —NO 2 , —OH, (1C-8C)alkoxy, aryloxy, carboxyl, (1C-8C)alkylthio, carboxylate, (1C-8C)alkyl, aryl, aryl(1C-8C)alkyl or halo(1C-8C)alkyl; or R a and R b form a 3-8 membered ring structure, optionally substituted with halogen, —CF 3 , —OCF 3 , —CN, —NO 2 , hydroxy, hydroxy(1C-4C)alkyl, (1C-8C)alkoxy, aryloxy, (1C-8C)alkylthio, carboxyl, carboxylate, (1C-8C)alkyl, aryl, aryl(1C-8C)alkyl, halo(1C-8C)alkyl.

3. The compound according to claim 1 , wherein R 1 is selected from H, halogen and CF 3 .

4. The compound according to claim 2 , wherein,

R 2 is —O(CH 2 ) m NR a R b , wherein m=2-3 and R a , R b are independently (1 C-5C)alkyl, (3C-5C)alkenyl, or aryl, which alkyl, alkenyl and aryl can be optionally substituted with OH or methoxy, or R a and R b form a 4-7 membered ring structure selected from the list: azetidine, pyrrolidine, 3-pyrroline, piperidine, piperazine, tetrahydropyridine, morpholine, thiomorpholine, thiazolidine, homopiperidine, tetrahydroquinoline and 6-azabicyclor[3.2.1]octane, which 4-7 membered ring structure can optionally be substituted with OH, methoxy, acetyl, carboxylate, (1C-3C)alkyl, phenyl, benzyl, and phenylethyl.

5. A method of treating an estrogen receptor related disorder selected from the group consisting of contraception, benign prostate hypertrophy, osteoporosis, Alzheimer's disease and depression, comprising administering an effective amount of the compound according to claim 1 to a patient in need thereof.

6. A pharmaceutical composition, comprising:

the compound of claim 1 , and

a pharmaceutically acceptable carrier.

7. The method of claim 5 , wherein the estrogen receptor related treatment is contraception.

8. The method of claim 5 , wherein the estrogen receptor related treatment is treatment of benign prostate hypertrophy.

9. The method of claim 5 , wherein the estrogen receptor related treatment is treatment of osteoporosis.

10. The method of claim 5 , wherein the estrogen receptor related treatment is treatment of Alzheimer's disease.

11. The method of claim 5 , wherein the estrogen receptor related treatment is treatment of depression.